Home › For J&J Prostate Cancer Is PARP For The Course
 

Keywords :   


For J&J Prostate Cancer Is PARP For The Course

2016-04-07 23:45:50| Food - Topix.net

Johnson & Johnson addressed two issues with one relatively small $35m payment: its position in prostate cancer and absence from PARP inhibition. The big pharma group locked up one of just two unpartnered assets in this rejuvenated class and has chosen to focus its work in prostate cancer, where Zytiga might soon run out of market exclusivity.

Tags: the cancer prostate prostate cancer

Category:Food and Related Products

Latest from this category

All news
»
12.10Atlantic Tropical Weather Outlook
12.10Eastern North Pacific Tropical Weather Outlook
11.10Five things we've learned from the Post Office boss
11.10Boeing to axe 17,000 jobs amid strike and quality concerns
11.10Tropical Storm Leslie Graphics
11.10Tropical Storm Leslie Forecast Discussion Number 38
11.10Tropical Storm Leslie Wind Speed Probabilities Number 38
11.10Tropical Storm Leslie Public Advisory Number 38
More »